UA96141C2 - Neutralising antibody having specificity for human il-6 - Google Patents

Neutralising antibody having specificity for human il-6

Info

Publication number
UA96141C2
UA96141C2 UAA200808897A UAA200808897A UA96141C2 UA 96141 C2 UA96141 C2 UA 96141C2 UA A200808897 A UAA200808897 A UA A200808897A UA A200808897 A UAA200808897 A UA A200808897A UA 96141 C2 UA96141 C2 UA 96141C2
Authority
UA
Ukraine
Prior art keywords
specificity
human
antibody
neutralising antibody
relates
Prior art date
Application number
UAA200808897A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ричард Эван Желинас
Митра Чудхури Сингхал
Йи Жанг
Эндрю Джордж Попплвэлл
Ральф Адамс
Original Assignee
Юсиби Фарма, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714544&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA96141(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсиби Фарма, С.А. filed Critical Юсиби Фарма, С.А.
Publication of UA96141C2 publication Critical patent/UA96141C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention relates to a humanised neutralising antibody having specificity for human IL- DNA sequence encoding thereof, a vector, a host cell, a method of producing an antibody. The invention further relates to a pharmaceutical composition comprising the antibody for use in the treatment or prophylaxis of a pathological disorder that is mediated by IL-6, or that is associated with an increased level of IL-6.
UAA200808897A 2005-12-09 2006-12-04 Neutralising antibody having specificity for human il-6 UA96141C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74892605P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
UA96141C2 true UA96141C2 (en) 2011-10-10

Family

ID=37714544

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200808897A UA96141C2 (en) 2005-12-09 2006-12-04 Neutralising antibody having specificity for human il-6

Country Status (28)

Country Link
US (5) US8075889B2 (en)
EP (3) EP2336181A1 (en)
JP (1) JP5183484B2 (en)
KR (2) KR101422523B1 (en)
CN (1) CN101356194B (en)
AR (1) AR057224A1 (en)
AU (1) AU2006323490B2 (en)
BR (1) BRPI0619595B8 (en)
CA (1) CA2632628C (en)
DK (1) DK1960430T3 (en)
EA (1) EA018044B1 (en)
EC (1) ECSP088613A (en)
ES (1) ES2525325T3 (en)
HK (1) HK1125113A1 (en)
HR (1) HRP20141214T1 (en)
IL (2) IL191600A (en)
MY (1) MY147217A (en)
NO (1) NO344847B1 (en)
NZ (1) NZ569234A (en)
PE (1) PE20070998A1 (en)
PL (1) PL1960430T3 (en)
PT (1) PT1960430E (en)
RS (1) RS53708B1 (en)
SI (1) SI1960430T1 (en)
TW (1) TWI390035B (en)
UA (1) UA96141C2 (en)
WO (1) WO2007066082A1 (en)
ZA (1) ZA200804594B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
DK1960430T3 (en) * 2005-12-09 2015-01-05 Ucb Pharma Sa ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMANT IL-6
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
JP5659014B2 (en) 2007-08-02 2015-01-28 ジリード バイオロジクス，インク． Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis and metastasis
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
BRPI0921665A2 (en) * 2008-11-13 2019-04-16 Femta Pharmaceuticals, Inc. Humanized anti-il-6 antibodies
WO2010065079A2 (en) 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
SG2014004816A (en) * 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
KR20120054077A (en) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. Methods and compositions for treatment of pulmonary fibrotic disorders
US8680246B2 (en) * 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
US9289467B2 (en) * 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
US20130149351A1 (en) * 2011-12-09 2013-06-13 University Of Southern California Polymer scaffolds and their use in the treatment of vision loss
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
CA2889181C (en) * 2012-10-22 2021-12-07 Fountain Biopharma Inc. Antibodies to interleukin-6 and uses thereof
KR20150070384A (en) * 2012-10-25 2015-06-24 메디뮨 엘엘씨 Stable, low viscosity antibody formulation
CA3023089A1 (en) * 2016-05-05 2017-11-09 The Trustees Of The University Of Pennsylvania Dna monoclonal antibodies targeting il-6 and cd126
CN106413047A (en) * 2016-10-31 2017-02-15 北京小米移动软件有限公司 Method and device for enabling intelligent device to be accessed to wireless network
EP3576790A4 (en) 2017-02-01 2020-12-23 Yale University Treatment of diuretic resistance
JP6950242B2 (en) * 2017-03-31 2021-10-13 ブラザー工業株式会社 Communication device
BR112020013519A2 (en) 2018-01-05 2020-12-01 Corvidia Therapeutics, Inc method for treating an inflammation.
KR20210070317A (en) 2018-09-28 2021-06-14 리브젠 바이오파마 코., 엘티디. Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
KR20220103957A (en) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 Anti-CD40 binding molecules and bi-specific antibodies comprising same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (en) 1987-07-01 1987-07-01 Novo Industri As immobilization
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies specifically binding to natural and recombinant interferon-beta2 and method of purification of said interferon-beta2
DE768377T1 (en) 1988-09-02 1998-01-02 Dyax Corp Production and selection of recombinant proteins with different binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69233750D1 (en) 1991-04-10 2009-01-02 Scripps Research Inst Libraries of heterodimeric receptors using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
JP3614183B2 (en) * 1993-05-31 2005-01-26 中外製薬株式会社 Reconstituted human antibody against human interleukin-6
FR2707882B1 (en) * 1993-07-23 1997-08-01 Immunotech Sa New protein anti-mediator therapeutic kits, preparation process and pharmaceutical compositions containing them.
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (en) 1994-01-31 2003-10-20 Univ Boston Polyclonal antibody libraries
FR2716640B1 (en) 1994-02-28 1996-05-03 Procedes Machines Speciales Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE69839992D1 (en) * 1997-03-21 2008-10-23 Chugai Pharmaceutical Co Ltd Prophylactic or therapeutic agents for the treatment of multiple sclerosis, with antagonist anti-IL6 receptor antibodies as the active ingredient
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
CN100374457C (en) * 2001-11-14 2008-03-12 森托科尔公司 Anti-IL-6 antibodies, compositions, methods and uses
CN1678744B (en) * 2002-08-30 2010-05-26 财团法人化学及血清疗法研究所 Human antihuman interleukin-6 antibody and fragment of the antibody
JP4603894B2 (en) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム Assays to identify antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005003169A2 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
DK1960430T3 (en) 2005-12-09 2015-01-05 Ucb Pharma Sa ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMANT IL-6

Also Published As

Publication number Publication date
US20120183996A1 (en) 2012-07-19
US9631015B2 (en) 2017-04-25
PL1960430T3 (en) 2015-03-31
KR101422523B1 (en) 2014-07-24
EP2336181A1 (en) 2011-06-22
RS53708B1 (en) 2015-04-30
BRPI0619595B8 (en) 2022-12-13
JP5183484B2 (en) 2013-04-17
SI1960430T1 (en) 2015-01-30
EA200801427A1 (en) 2008-12-30
NO20083066L (en) 2008-09-08
HK1125113A1 (en) 2009-07-31
NZ569234A (en) 2011-07-29
US8075889B2 (en) 2011-12-13
AU2006323490A1 (en) 2007-06-14
NO344847B1 (en) 2020-05-25
AR057224A1 (en) 2007-11-21
WO2007066082A1 (en) 2007-06-14
CN101356194A (en) 2009-01-28
ZA200804594B (en) 2010-08-25
BRPI0619595A2 (en) 2011-10-04
EP2314626A1 (en) 2011-04-27
US20070154481A1 (en) 2007-07-05
TWI390035B (en) 2013-03-21
ES2525325T3 (en) 2014-12-22
CA2632628C (en) 2016-01-19
IL191600A0 (en) 2008-12-29
KR101413451B1 (en) 2014-07-10
CA2632628A1 (en) 2007-06-14
AU2006323490B2 (en) 2012-05-24
EA018044B1 (en) 2013-05-30
BRPI0619595A8 (en) 2019-01-15
US20140024077A1 (en) 2014-01-23
PE20070998A1 (en) 2007-10-09
BRPI0619595B1 (en) 2020-09-15
KR20080077271A (en) 2008-08-21
EP1960430B1 (en) 2014-09-24
US20160039929A1 (en) 2016-02-11
MY147217A (en) 2012-11-14
EP1960430A1 (en) 2008-08-27
PT1960430E (en) 2015-01-05
US20170182159A1 (en) 2017-06-29
US8486662B2 (en) 2013-07-16
IL242434B (en) 2018-04-30
IL191600A (en) 2015-11-30
CN101356194B (en) 2013-06-12
ECSP088613A (en) 2008-08-29
KR20130100386A (en) 2013-09-10
TW200728466A (en) 2007-08-01
US9096668B2 (en) 2015-08-04
JP2009518023A (en) 2009-05-07
DK1960430T3 (en) 2015-01-05
HRP20141214T1 (en) 2015-02-13

Similar Documents

Publication Publication Date Title
UA96141C2 (en) Neutralising antibody having specificity for human il-6
WO2017191274A3 (en) Rna encoding a therapeutic protein
MY171038A (en) Bispecific antigen binding molecules
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
MX2009006471A (en) Engineered anti-tslp antibody.
UA90048C2 (en) Conditioned blood composition and method for its production
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EA201492149A8 (en) ST2 Antigen Binding Proteins
MX2009003973A (en) Antibody molecules which bind il-17a and il-17f.
MX2012004084A (en) Siglec 15 antibodies in treating bone loss-related disease.
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
MX2014006158A (en) Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles.
PH12013502205A1 (en) Antibodies to il-6 and their uses
JO3097B1 (en) c-Met Antibodies
MY157173A (en) Modified humanised anti-interleukin-18
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA200700175A1 (en) COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY DISEASES
MX2010000537A (en) Monoclonal antibodies against glypican-3.
MX2010009190A (en) HUMANIZED ANTI-C5aR ANTIBODIES.
MX361929B (en) Neutralizing anti-ccl20 antibodies.
WO2007025977A8 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
MX2009013410A (en) Biomarkers for predicting anti-tnf responsiveness or non-responsiveness.
MX2011012039A (en) Blocking anti-dkk-1 antibodies and their uses.